NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V.

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, alleging material misstatements regarding the company's Huntington's disease gene therapy drug [1]. Group 1: Lawsuit Details - The lawsuit, titled Scocco v. uniQure N.V., was filed in the United States District Court for the Southern District of New York [1]. - The class period for the lawsuit is defined as September 24, 2025, to October 31, 2025, with a deadline for investors to seek lead plaintiff status by April 13, 2026 [1]. - The allegations include misleading statements about the Phase I/II clinical trials of uniQure's leading drug candidate, AMT-130, and the timeline for its Biologics License Application (BLA) submission to the FDA [1]. Group 2: Allegations Against uniQure - The complaint claims that uniQure misrepresented the approval status of the Pivotal Study design by the FDA and downplayed the likelihood of delays in the BLA timeline due to the need for additional studies [1]. - It is alleged that the defendants failed to disclose material adverse facts about uniQure's business and operations, leading to a lack of reasonable basis for their statements regarding the company's prospects [1]. Group 3: Investor Actions - Investors affected by the alleged fraud are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and to consider filing to be a lead plaintiff by the specified deadline [1]. - The lead plaintiff process allows investors to represent the class in directing the litigation, with the potential for recovery not affected by the decision to serve as lead plaintiff [1].